StockData
Innoviva, Inc. logo

Innoviva, Inc. (INVA) stock

INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)

Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –

Innoviva total assets

Total assets on the balance sheet at the end of each period.

Innoviva's total assets was $1.54B at Sep 30, 2026. For fiscal 2025 it was $1.64B, up 25.7% from the year before. Over ten years it grew 14.9% a year on average. The highest annual figure on record is $1.64B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.64B+25.7%
FY2024Dec 31, 2024$1.30B+4.6%
FY2023Dec 31, 2023$1.24B+1.0%
FY2022Dec 31, 2022$1.23B+32.9%
FY2021Dec 31, 2021$926.40M-7.3%
FY2020Dec 31, 2020$999.57M+37.9%
FY2019Dec 31, 2019$724.83M+32.2%
FY2018Dec 31, 2018$548.19M+49.2%
FY2017Dec 31, 2017$367.34M-3.1%
FY2016Dec 31, 2016$379.00M-7.3%
FY2015Dec 31, 2015$408.93M-21.6%
FY2014Dec 31, 2014$521.65M-23.4%
FY2013Dec 31, 2013$681.26M+84.8%
FY2012Dec 31, 2012$368.58M+42.4%
FY2011Dec 31, 2011$258.78M-21.9%
FY2010Dec 31, 2010$331.20M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.54B+7.6%
Q2 FY2026Jun 30, 2026$1.70B+27.7%
Q1 FY2026Mar 31, 2026$1.84B+46.4%
Q4 FY2025Dec 31, 2025$1.64B+25.7%
Q3 FY2025Sep 30, 2025$1.43B+16.0%
Q2 FY2025Jun 30, 2025$1.33B+8.9%
Q1 FY2025Mar 31, 2025$1.25B-1.0%
Q4 FY2024Dec 31, 2024$1.30B+4.6%
Q3 FY2024Sep 30, 2024$1.23B+3.7%
Q2 FY2024Jun 30, 2024$1.22B+9.5%
Q1 FY2024Mar 31, 2024$1.27B+12.2%
Q4 FY2023Dec 31, 2023$1.24B+1.0%
Q3 FY2023Sep 30, 2023$1.19B-10.5%
Q2 FY2023Jun 30, 2023$1.12B-1.7%
Q1 FY2023Mar 31, 2023$1.13B+2.0%
Q4 FY2022Dec 31, 2022$1.23B+32.9%
Q3 FY2022Sep 30, 2022$1.33B+49.6%
Q2 FY2022Jun 30, 2022$1.14B+44.2%
Q1 FY2022Mar 31, 2022$1.11B+1.8%
Q4 FY2021Dec 31, 2021$926.40M-7.3%
Q3 FY2021Sep 30, 2021$887.24M-3.8%
Q2 FY2021Jun 30, 2021$789.15M-10.3%
Q1 FY2021Mar 31, 2021$1.09B+38.1%
Q4 FY2020Dec 31, 2020$999.57M+37.9%
Q3 FY2020Sep 30, 2020$922.26M+36.4%
Q2 FY2020Jun 30, 2020$879.62M+36.9%
Q1 FY2020Mar 31, 2020$788.01M+33.5%
Q4 FY2019Dec 31, 2019$724.83M+32.2%
Q3 FY2019Sep 30, 2019$675.95M+143.4%
Q2 FY2019Jun 30, 2019$642.31M+89.6%
Q1 FY2019Mar 31, 2019$590.11M+113.2%
Q4 FY2018Dec 31, 2018$548.19M+49.2%
Q3 FY2018Sep 30, 2018$277.69M-29.0%
Q2 FY2018Jun 30, 2018$338.69M-9.0%
Q1 FY2018Mar 31, 2018$276.75M-29.4%
Q4 FY2017Dec 31, 2017$367.34M-3.1%
Q3 FY2017Sep 30, 2017$390.97M–
Q2 FY2017Jun 30, 2017$372.02M–
Q1 FY2017Mar 31, 2017$391.87M–
Q4 FY2016Dec 31, 2016$379.00M–

More Innoviva figures

See a number that looks wrong?